Modern views on the recurrence of meningiomas

Meningiomas are common tumors of the central nervous system. Grade I meningiomas  are generally considered to be "benign". However, a certain percentage of these tumors have a more aggressive course, similar to malignant tumors. Numerous observations have shown that even in the...

Full description

Bibliographic Details
Main Authors: Mykola O. Guk, Mykhailo B. Bandrivskyi, Olena O. Danevych, Artur O. Mumlev, Dmitry M. Tsyurupa, Andrey A. Chukov, Vasyl V. Kondratyuk
Format: Article
Language:English
Published: Romodanov Neurosurgery Institute 2022-06-01
Series:Ukrainian Neurosurgical Journal
Online Access:https://theunj.org/article/view/243332
_version_ 1797350802694602752
author Mykola O. Guk
Mykhailo B. Bandrivskyi
Olena O. Danevych
Artur O. Mumlev
Dmitry M. Tsyurupa
Andrey A. Chukov
Vasyl V. Kondratyuk
author_facet Mykola O. Guk
Mykhailo B. Bandrivskyi
Olena O. Danevych
Artur O. Mumlev
Dmitry M. Tsyurupa
Andrey A. Chukov
Vasyl V. Kondratyuk
author_sort Mykola O. Guk
collection DOAJ
description Meningiomas are common tumors of the central nervous system. Grade I meningiomas  are generally considered to be "benign". However, a certain percentage of these tumors have a more aggressive course, similar to malignant tumors. Numerous observations have shown that even in the case of radical removal of the tumor, the latter recur within the next 10 years. Recent molecular studies have shed new light on meningioma subtypes, their behavior, the prospect of new treatment, and prognostic features for patients. The study of V.E. Clark et al. found a number of mutations in NF2 meningiomas, namely TRAF7 (tumor necrosis factor receptor 7 factor), KLF4 (Kruppel-like factor 4c), AKT1 and SMO. The pattern between the type of mutation and the tumor location was established: posterior cranial fossa, parasagittal area, falx, torculae and intraventricular sections - loss of NF2 or chromosome 22, olfactory groove and middle cranial fossa - KLF4 / TRAF7, olfactory groove, - PIK3CA, middle parts of the anterior cranial fossa and middle cranial fossa - AKT1 / POLR2, olfactory groove - SMO. The selection criteria in the study, which analyzed data from 469 meningiomas of a known molecular subgroup, were the degree of resection, postoperative irradiation, postoperative neuroimaging and time to recurrence (if present). Molecular subgroups of meningiomas had different clinical manifestations during the two years of follow-up, with several aggressive subgroups (NF2, PI3K, HH, TRAF7) recurring at an average rate 22 times faster than less aggressive tumors (KLF4, POLR2A, SMARCB1). PI3K-activated meningiomas recurred earlier than tumors in other groups. The potentially more aggressive group of meningiomas with HH, NF2, and TRAF7 mutations demonstrated a high recurrence rate after 60 months of follow-up (35.3, 43.7, and 36.4%, respectively), whereas most tumor recurrences  with PI3K mutations were reported within the first 24 months (75,0%). Classification of meningiomas by genomic mutations is a promising tool. Its introduction into clinical practice will make it possible to predict the aggressiveness of meningiomas and the risk of their recurrence, which will help to give a more accurate prognosis for patients and develop effective therapeutic methods for these tumors.
first_indexed 2024-03-08T12:51:24Z
format Article
id doaj.art-6006fd25600e496e80fa8ec906e0f463
institution Directory Open Access Journal
issn 2663-9084
2663-9092
language English
last_indexed 2024-03-08T12:51:24Z
publishDate 2022-06-01
publisher Romodanov Neurosurgery Institute
record_format Article
series Ukrainian Neurosurgical Journal
spelling doaj.art-6006fd25600e496e80fa8ec906e0f4632024-01-20T09:13:02ZengRomodanov Neurosurgery InstituteUkrainian Neurosurgical Journal2663-90842663-90922022-06-012823710.25305/unj.243332Modern views on the recurrence of meningiomas Mykola O. Guk0https://orcid.org/0000-0003-0614-7364Mykhailo B. Bandrivskyi1https://orcid.org/0000-0001-6315-5518Olena O. Danevych2https://orcid.org/0000-0003-3766-8402Artur O. Mumlev3https://orcid.org/0000-0002-6483-3920Dmitry M. Tsyurupa4https://orcid.org/0000-0001-7651-5711Andrey A. Chukov5https://orcid.org/0000-0001-5278-5119Vasyl V. Kondratyuk6Romodanov Neurosurgery Institute, Kyiv, UkraineRomodanov Neurosurgery Institute, Kyiv, UkraineRomodanov Neurosurgery Institute, Kyiv, UkraineRomodanov Neurosurgery Institute, Kyiv, UkraineRomodanov Neurosurgery Institute, Kyiv, UkraineRomodanov Neurosurgery Institute, Kyiv, UkraineRomodanov Neurosurgery Institute, Kyiv, Ukraine Meningiomas are common tumors of the central nervous system. Grade I meningiomas  are generally considered to be "benign". However, a certain percentage of these tumors have a more aggressive course, similar to malignant tumors. Numerous observations have shown that even in the case of radical removal of the tumor, the latter recur within the next 10 years. Recent molecular studies have shed new light on meningioma subtypes, their behavior, the prospect of new treatment, and prognostic features for patients. The study of V.E. Clark et al. found a number of mutations in NF2 meningiomas, namely TRAF7 (tumor necrosis factor receptor 7 factor), KLF4 (Kruppel-like factor 4c), AKT1 and SMO. The pattern between the type of mutation and the tumor location was established: posterior cranial fossa, parasagittal area, falx, torculae and intraventricular sections - loss of NF2 or chromosome 22, olfactory groove and middle cranial fossa - KLF4 / TRAF7, olfactory groove, - PIK3CA, middle parts of the anterior cranial fossa and middle cranial fossa - AKT1 / POLR2, olfactory groove - SMO. The selection criteria in the study, which analyzed data from 469 meningiomas of a known molecular subgroup, were the degree of resection, postoperative irradiation, postoperative neuroimaging and time to recurrence (if present). Molecular subgroups of meningiomas had different clinical manifestations during the two years of follow-up, with several aggressive subgroups (NF2, PI3K, HH, TRAF7) recurring at an average rate 22 times faster than less aggressive tumors (KLF4, POLR2A, SMARCB1). PI3K-activated meningiomas recurred earlier than tumors in other groups. The potentially more aggressive group of meningiomas with HH, NF2, and TRAF7 mutations demonstrated a high recurrence rate after 60 months of follow-up (35.3, 43.7, and 36.4%, respectively), whereas most tumor recurrences  with PI3K mutations were reported within the first 24 months (75,0%). Classification of meningiomas by genomic mutations is a promising tool. Its introduction into clinical practice will make it possible to predict the aggressiveness of meningiomas and the risk of their recurrence, which will help to give a more accurate prognosis for patients and develop effective therapeutic methods for these tumors.https://theunj.org/article/view/243332
spellingShingle Mykola O. Guk
Mykhailo B. Bandrivskyi
Olena O. Danevych
Artur O. Mumlev
Dmitry M. Tsyurupa
Andrey A. Chukov
Vasyl V. Kondratyuk
Modern views on the recurrence of meningiomas
Ukrainian Neurosurgical Journal
title Modern views on the recurrence of meningiomas
title_full Modern views on the recurrence of meningiomas
title_fullStr Modern views on the recurrence of meningiomas
title_full_unstemmed Modern views on the recurrence of meningiomas
title_short Modern views on the recurrence of meningiomas
title_sort modern views on the recurrence of meningiomas
url https://theunj.org/article/view/243332
work_keys_str_mv AT mykolaoguk modernviewsontherecurrenceofmeningiomas
AT mykhailobbandrivskyi modernviewsontherecurrenceofmeningiomas
AT olenaodanevych modernviewsontherecurrenceofmeningiomas
AT arturomumlev modernviewsontherecurrenceofmeningiomas
AT dmitrymtsyurupa modernviewsontherecurrenceofmeningiomas
AT andreyachukov modernviewsontherecurrenceofmeningiomas
AT vasylvkondratyuk modernviewsontherecurrenceofmeningiomas